All-trans retinoic acid (ATRA) suppresses transcription of human papillomavirus type 16 (HPV16) in a dose-dependent manner.

Earlier we found that SiHa cervical squamous carcinoma cells that harbor HPV type 16 respond to ATRA treatment in a dose-dependent manner: high-dose (10(-5)-10(-4) M) but not low-dose (10(-7)-10(-6) M) ATRA induced growth arrest. Growth of HPV-infected cells is highly dependent on the expression of the viral E6/E7 proteins. Thus, targeting expression of the viral E6/E7 genes might influence growth properties of HPV-infected cells. Here, we demonstrated that high-dose ATRA inhibited expression of HPV16 E7 through suppression of the HPV16 promoter (p97) activity. Gelshift assay (EMSA) revealed that binding of the AP-1 transcription factor to an oligonucleotide originated from the HPV type 16 promoter was diminished after high-dose, but not low-dose ATRA treatment. This suggests that high-dose ATRA suppresses HPV 16 promoter activity, at least in part, via a decreased AP-1 binding. Our data might be useful in treatment of cervical dysplasias and/or carcinomas.

[1]  A. Taniguchi,et al.  Induction of the HPV16 enhancer activity byJun-B and c-Fos through cooperation of the promoter-proximal AP-1 site and the epithelial cell type- specific regulatory element in fibroblasts , 1996, Virus Genes.

[2]  L. Laimins,et al.  Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation , 2003, Oncogene.

[3]  I. Arany,et al.  A functional interferon regulatory factor-1 (IRF-1)-binding site in the upstream regulatory region (URR) of human papillomavirus type 16. , 2003, Virology.

[4]  I. Arany,et al.  All-trans-retinoic acid activates caspase-1 in a dose-dependent manner in cervical squamous carcinoma cells. , 2003, Anticancer research.

[5]  C. Woodworth.  HPV innate immunity. , 2002, Frontiers in bioscience : a journal and virtual library.

[6]  I. Arany,et al.  Suppression of Growth by All-trans Retinoic Acid Requires Prolonged Induction of Interferon Regulatory Factor 1 in Cervical Squamous Carcinoma (SiHa) Cells , 2002, Clinical and Vaccine Immunology.

[7]  Minoru Irahara,et al.  Human papilloma virus (HPV) and cervical cancer. , 2002, The journal of medical investigation : JMI.

[8]  I. Arany,et al.  Interleukin-10 induces transcription of the early promoter of human papillomavirus type 16 (HPV16) through the 5'-segment of the upstream regulatory region (URR). , 2002, Antiviral research.

[9]  P. Lefebvre,et al.  Retinoic Acid Receptors Inhibit AP1 Activation by Regulating Extracellular Signal-Regulated Kinase and CBP Recruitment to an AP1-Responsive Promoter , 2002, Molecular and Cellular Biology.

[10]  K. Münger.  The role of human papillomaviruses in human cancers. , 2002, Frontiers in bioscience : a journal and virtual library.

[11]  P. Whelan.  Retinoids in Chemoprevention , 1999, European Urology.

[12]  P. Matarrese,et al.  Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-alpha, IFN-beta and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21. , 1999, European cytokine network.

[13]  B. Narayanan,et al.  The effect of all-trans and 9-cis retinoic acid on the steady state level of HPV16 E6/E7 mRNA and cell cycle in cervical carcinoma cells. , 1998, Life sciences.

[14]  C. Desaintes,et al.  Control of papillomavirus DNA replication and transcription. , 1996, Seminars in cancer biology.

[15]  S. Lippman,et al.  Second international cancer chemoprevention conference. , 1994, Cancer research.

[16]  H. Hausen,et al.  Retinoic acid‐mediated repression of human papillomavirus 18 transcription and different ligand regulation of the retinoic acid receptor beta gene in non‐tumorigenic and tumorigenic HeLa hybrid cells. , 1992, The EMBO journal.

[17]  L. Banks,et al.  Analysis of human papillomavirus sequences in cell lines recently derived from cervical cancers. , 1988, Cancer research.